Clinical Trial: Personalized Sequence for Thoracic, Esophageal, and H&N Cancer

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: Establishment of Personalized Cancer Medicine Using Samsung Cancer Sequencing Platform in Lung Cancer/Mediastinal Tumor/ Head & Neck/Esophageal Cancer/Rare Cancer (Per

Brief Summary: The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information Therefore, a big data of genome-clinical information is important.

Detailed Summary: To determine the feasibility of the use of tumor's molecular profiling and targeted therapies in the treatment of advanced cancer and to determine the clinical outcome(PFS, duration of response and overall survival) of patients with advanced cancer, the investigators are going to take a fresh tissue of patients and process molecular profiling.
Sponsor: Samsung Medical Center

Current Primary Outcome: the spectrum of targetable genetic mutation in evaluated cancer specimens (for example, % of EGFR T790M mutation, BRAF mutation, or ALK mutation) [ Time Frame: 3 years ]

The pattern of the tumor's molecular profiling in advanced thoracic (lung, esophagus, or tthymic) cancer


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Samsung Medical Center

Dates:
Date Received: November 19, 2014
Date Started: November 2013
Date Completion: December 2017
Last Updated: April 19, 2016
Last Verified: April 2016